Diffuse large B-cell lymphoma is an aggressive but often treatable form of cancer affecting the immune system. While this disease grows rapidly and requires immediate attention, modern medicine offers multiple approaches to bring it under control, ranging from well-established chemotherapy combinations to cutting-edge therapies currently being tested in research settings. Understanding your treatment options can help you work with your healthcare team to find the best path forward.

How Treatment Aims to Help Patients with Diffuse Large B-Cell Lymphoma

When someone receives a diagnosis of diffuse large B-cell lymphoma, the primary goal of treatment is to eliminate the cancer cells and achieve long-term remission or even a cure. Despite being a fast-growing cancer, this condition often responds remarkably well to treatment, especially when caught early and addressed promptly.^[1] The specific treatment approach depends on several factors, including how far the disease has spread, the patient’s age and overall health, and certain biological features of the lymphoma cells themselves.^[2]

Healthcare providers use a variety of methods to treat diffuse large B-cell lymphoma, from standard therapies that have been refined over decades to innovative approaches being explored in clinical trials. The most common initial strategy involves combining chemotherapy drugs with targeted therapies that specifically attack cancer cells while sparing healthy tissue. In some situations, radiation therapy, stem cell transplantation, or advanced immunotherapies may also play a role in the treatment plan.^[1]

For many patients with this disease, the outlook can be surprisingly positive. About 75% of people treated with standard chemotherapy-based regimens respond well to initial therapy, and a significant proportion achieve long-lasting remission.^[7] However, treatment decisions are highly individualized. Your medical team will consider not just the stage of the disease but also your personal circumstances and preferences when recommending a course of action.

Standard Treatment Approaches

The backbone of treatment for diffuse large B-cell lymphoma has been a chemotherapy regimen known as R-CHOP, which stands for rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.^[9] This combination has become the gold standard because it addresses the disease from multiple angles simultaneously. Each drug in the combination works differently to attack cancer cells, making it harder for the lymphoma to resist treatment.

Rituximab is a monoclonal antibody, which means it’s a laboratory-made protein that mimics the immune system’s ability to fight off harmful cells. It specifically targets a protein called CD20 found on the surface of B cells, including cancerous ones. By attaching to this protein, rituximab marks cancer cells for destruction by the body’s immune system.^[14] The chemotherapy drugs that make up the “CHOP” part of the regimen work by interfering with cancer cell growth and division in various ways. Cyclophosphamide and doxorubicin damage the DNA inside cancer cells, vincristine disrupts the structures that cells need to divide, and prednisone is a steroid that has both anti-inflammatory and anti-cancer effects.

Treatment with R-CHOP typically involves receiving the drugs in cycles, usually once every 21 days, for a total of six to eight cycles. This means most patients complete their treatment within about six months.^[14] The treatment is usually given through an intravenous line in a hospital or clinic setting, followed by a recovery period at home. During this recovery time, the body works to repair healthy cells that may have been affected by the chemotherapy.

Another treatment option is R-EPOCH, which uses similar drugs but administers them differently. The “E” stands for etoposide, which is added to the regimen, and the drugs are given as a continuous infusion over several days rather than as a single dose.^[9] This approach may be preferred in certain situations, such as when the disease has specific aggressive features or in patients with HIV-related lymphoma.

The duration of treatment varies depending on how well the disease responds and how extensive it is at diagnosis. For patients with limited-stage disease (confined to one or two adjacent areas), treatment may consist of just three to four cycles of chemotherapy followed by radiation therapy to the affected area.^[16] Radiation uses high-energy beams to kill cancer cells in specific locations and is particularly useful when the disease is localized.

Side effects from standard treatment are common and can include decreased blood cell counts, which increases the risk of infection, anemia, and bleeding. Patients often experience fatigue, nausea, hair loss, and mouth sores. The specific side effects and their severity vary from person to person. Doxorubicin can affect the heart, so doctors monitor cardiac function during treatment. Vincristine may cause nerve damage leading to numbness or tingling in the hands and feet, a condition called peripheral neuropathy.^[4]

To help prevent serious infections during treatment, doctors may prescribe medications called growth factors, such as Neulasta, which stimulate the bone marrow to produce more white blood cells. Patients are also closely monitored with regular blood tests to ensure their blood counts remain safe throughout the treatment course.

Innovative Therapies in Clinical Trials

For patients who don’t respond to initial treatment or whose disease returns after remission, the landscape of available therapies has expanded dramatically in recent years. Clinical trials are research studies that test new treatments to see if they are safe and effective. These trials operate in phases, with Phase I focusing on safety, Phase II examining whether the treatment works, and Phase III comparing the new therapy to current standard treatments.

One of the most exciting developments in treating diffuse large B-cell lymphoma is CAR T-cell therapy, a form of immunotherapy that has been approved for use in patients with relapsed or refractory disease.^[11] This revolutionary approach involves removing a patient’s own immune T-cells from their blood, genetically modifying them in a laboratory to recognize and attack lymphoma cells, and then infusing them back into the patient. The modified cells are engineered to target a protein called CD19 found on B cells.

Three CAR T-cell therapies are currently approved for diffuse large B-cell lymphoma: axicabtagene ciloleucel (Yescarta), lisocabtagene maraleucel (Breyanzi), and tisagenlecleucel (Kymriah).^[15] These treatments are now approved as second-line therapy, meaning they can be used after initial treatment fails, rather than waiting until the disease has relapsed multiple times. In the case of axicabtagene ciloleucel, studies have shown it provides a survival advantage compared to the traditional approach of chemotherapy followed by stem cell transplant.^[12]

CAR T-cell therapy has produced remarkable results, with roughly 30% to 40% of patients achieving long-term remission that may represent a cure.^[12] The therapy does carry risks, particularly cytokine release syndrome (CRS), which occurs when the activated T-cells release large amounts of inflammatory proteins into the bloodstream. This can cause fever, low blood pressure, and difficulty breathing. Another potential complication is neurotoxicity, which can cause confusion, seizures, or difficulty speaking. Lisocabtagene maraleucel tends to have lower rates of these severe side effects, making it easier to administer on an outpatient basis in some cases.^[12]

Bispecific antibodies represent another innovative approach being used in clinical trials and increasingly in clinical practice for relapsed disease. These engineered proteins have two arms: one binds to CD20 on lymphoma cells, and the other binds to CD3 on T-cells. By physically bringing these two cell types together, bispecific antibodies enable the patient’s own T-cells to kill the cancer cells directly.^[12]

Two bispecific antibodies have received approval for diffuse large B-cell lymphoma: epcoritamab (Epkinly) and glofitamab (Columvi).^[15] These therapies have shown high response rates even in patients who have received multiple prior treatments. The treatment requires careful monitoring, especially during the first few doses, as patients can develop cytokine release syndrome. To minimize this risk, doctors use a step-up dosing approach, starting with small doses and gradually increasing them. Some patients also receive a medication called tocilizumab before treatment to further reduce the risk of severe reactions.^[12]

Antibody drug conjugates are another class of targeted therapy that combines the precision of antibodies with the cell-killing power of chemotherapy. These molecules consist of an antibody that recognizes a specific protein on cancer cells, linked to a potent chemotherapy drug. When the antibody binds to its target, the entire complex is pulled inside the cancer cell, where the chemotherapy drug is released to do its work.

Polatuzumab vedotin (Polivy) targets CD79b, a protein found on B cells, and has been approved in combination with chemotherapy for certain patients with diffuse large B-cell lymphoma.^[9] Clinical trials have shown that adding polatuzumab vedotin to standard chemotherapy improves outcomes, particularly in patients with the activated B-cell subtype of the disease. Another antibody drug conjugate, loncastuximab tesirine, which targets CD19, is available for patients with relapsed or refractory disease.^[12]

For patients whose disease has specific molecular characteristics, targeted therapies may offer additional options. Ibrutinib (Imbruvica), a drug that blocks a protein called Bruton’s tyrosine kinase (BTK), has been studied in clinical trials for diffuse large B-cell lymphoma.^[9] Research has shown that the activated B-cell subtype of the disease is much more responsive to ibrutinib than the germinal center subtype. Based on these findings, international clinical trials are underway comparing standard chemotherapy with and without ibrutinib to determine if this targeted approach should become part of standard care.

Other therapies being explored in clinical trials include combinations of existing drugs in new sequences, checkpoint inhibitors that help the immune system recognize cancer cells, and agents that target specific genetic abnormalities found in some lymphomas. Lenalidomide (Revlimid) combined with tafasitamab (Monjuvi), a monoclonal antibody targeting CD19, represents another option for relapsed or refractory disease that emerged from clinical trial research.^[15]

Clinical trials for diffuse large B-cell lymphoma are conducted at major cancer centers throughout the United States, Europe, and other regions around the world. Eligibility for these trials depends on factors such as the number of prior treatments received, the patient’s overall health status, whether the disease expresses certain proteins on its surface, and sometimes the specific genetic features of the lymphoma cells. Patients interested in participating in clinical trials should discuss this option with their oncologist, who can help identify appropriate studies and facilitate enrollment.

Treatment for Disease That Returns or Doesn’t Respond

When diffuse large B-cell lymphoma comes back after treatment or doesn’t respond adequately to initial therapy, the situation becomes more challenging but is far from hopeless. For patients who are young enough and healthy enough to tolerate intensive treatment, high-dose chemotherapy followed by autologous stem cell transplantation has traditionally been a standard approach.^[15] In this procedure, the patient’s own blood-forming stem cells are collected from the bloodstream before receiving very high doses of chemotherapy that would otherwise be too toxic to the bone marrow. After the chemotherapy, the saved stem cells are returned to the patient’s body, where they travel to the bone marrow and begin producing new blood cells.

However, the landscape has shifted with the approval of CAR T-cell therapy as a second-line treatment option. Clinical trials have shown that for many patients, CAR T-cell therapy produces better outcomes than the traditional approach of salvage chemotherapy followed by transplant.^[12] This has led to changes in how doctors approach treatment sequencing for relapsed disease.

For patients who are not candidates for CAR T-cell therapy due to age, medical comorbidities, or logistical challenges such as difficulty traveling to specialized treatment centers, several other effective options exist. These include the antibody drug conjugates and bispecific antibodies discussed earlier, as well as various chemotherapy combinations specifically designed for relapsed disease. Regimens with names like ICE (ifosfamide, carboplatin, and etoposide), DHAP (dexamethasone, cisplatin, and cytarabine), and gemcitabine-based therapies are commonly used in this setting.^[15]

Another option for some patients is bendamustine combined with rituximab, or the combination of lenalidomide with rituximab, which have shown activity in relapsed disease.^[15] For patients whose disease has relapsed multiple times and become resistant to many treatments, newer agents like selinexor (Xpovio), which blocks the export of certain proteins from the nucleus of cancer cells, may be considered.

Most Common Treatment Methods

• Chemoimmunotherapy (R-CHOP and related regimens)
  • Combination of rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone given in 21-day cycles for typically six to eight cycles
  • The most widely used first-line treatment for diffuse large B-cell lymphoma with proven effectiveness
  • Alternative regimen R-EPOCH uses continuous infusion and includes etoposide instead of standard dosing
  • Modified regimen pola-R-CHP replaces vincristine with polatuzumab vedotin for higher-risk patients
• CAR T-Cell Therapy
  • Genetically modified patient’s own T-cells to target CD19 protein on lymphoma cells
  • Approved therapies include axicabtagene ciloleucel, lisocabtagene maraleucel, and tisagenlecleucel
  • Used as second-line treatment for relapsed or refractory disease with potential for long-term remission in 30-40% of patients
  • Requires monitoring for cytokine release syndrome and neurotoxicity
• Bispecific Antibodies
  • Epcoritamab and glofitamab work by bringing T-cells and lymphoma cells together to trigger cancer cell destruction
  • Effective even in third-line setting for patients who have received multiple prior treatments
  • Require step-up dosing to minimize cytokine release syndrome risk
• Antibody Drug Conjugates
  • Polatuzumab vedotin targets CD79b protein and delivers chemotherapy directly to cancer cells
  • Loncastuximab tesirine targets CD19 antigen for patients with relapsed disease
  • Combine precision of targeted therapy with cell-killing power of chemotherapy
• Radiation Therapy
  • High-energy beams used to kill cancer cells in specific locations
  • Often combined with chemotherapy for limited-stage disease
  • May be used after chemotherapy for areas of bulky disease or incomplete response
• Stem Cell Transplantation
  • Autologous transplant uses patient’s own stem cells after high-dose chemotherapy
  • Traditionally used for relapsed or refractory disease before CAR T-cell therapy became available
  • Allows use of higher chemotherapy doses than would otherwise be tolerable
• Targeted Therapy
  • Ibrutinib blocks Bruton’s tyrosine kinase particularly effective in activated B-cell subtype
  • Lenalidomide combined with tafasitamab targets immune pathways
  • Selinexor blocks protein export from cancer cell nucleus